Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.58 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPN | P05981 | 1/20 | 0.31 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6230800 | 0.97 | GABRA1 (0.56) | GABRA1GABRB1CYP3A4TP53LMNA | |
| SCHEMBL19507086 | 0.85 | GABRA1 (0.45) | GABRA1GABRB1CYP3A4TP53TSHR | |
| SCHEMBL19506266 | 0.80 | GABRA1 (0.44) | GABRA1GABRB1TSHRPOLBGAA | |
| SCHEMBL19507083 | 0.79 | GABRA1 (0.58) | GABRA1GABRB1TP53LMNAHTT | |
| SCHEMBL26758068 | 0.78 | GABRA1 (0.52) | GABRA1GABRB1CYP3A4TP53LMNA | |
| SCHEMBL22525916 | 0.78 | GABRA1 (0.64) | GABRA1GABRB1CYP3A4TP53LMNA | |
| SCHEMBL2155116 | 0.78 | ALDH1A1 (0.38) | GABRA1GABRB1CYP3A4TP53LMNA | |
| SCHEMBL461449 | 0.78 | CA1 (0.55) | GABRA1GABRB1CYP3A4TP53LMNA | |
| SCHEMBL6405781 | 0.77 | GABRA1 (0.50) | GABRA1GABRB1CYP3A4TP53LMNA | |
| Hydrochloric Acid SCHEMBL5431425 | 0.76 | GAA (0.38) | GABRA1GABRB1CYP3A4LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260040813-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-02-05 | — | — | US | disclosed |
| US-12495715-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| CN-113582889-B | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2024-09-20 | — | — | CN | disclosed |
| US-12012392-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| US-11981667-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-05-14 | — | — | US | disclosed |
| US-20240140973-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-05-02 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-6461822-B2 | THERAPEUTIC TARGETS FOR AGENTS THAT SUPPRESS THE RELEASE OF INFLAMMATORY MEDIATORS SUCH AS INTERLEUKIN IL-1 AND IL-1 BETA | PFIZER INC. | 2002-10-08 | — | — | US | disclosed |
| US-6433009-B1 | TREATMENT OF AUTOIMMUNE, CARDIOVASCULAR, NERVOUS SYSTEM, GASTROINTESTINAL, RESPIRATORY SYSTEM, AND VIRAL DISORDERS; ANTIDIABETIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANTIDEPRESSANT AGENTS | PFIZER INC | 2002-08-13 | — | — | US | disclosed |
| EP-1214087-A1 | COMBINATION TREATMENT WITH IL-1RA AND COMPOUNDS THAT INHIBIT IL-1 PROCESSING AND RELEASE | Pfizer Products Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| US-20020034764-A1 | DIARYLSULFONYLUREA BINDING PROTEINS | GABEL CHRISTOPHER A (US) | 2002-03-21 | — | — | US | disclosed |
| WO-2001019390-A1 | COMBINATION TREATMENT WITH IL-1RA AND DIARYL SULPHONYL UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0987552-A2 | Diarylsulfonylurea binding proteins | Pfizer Products Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0964849-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998032733-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| EP-0152021-A2 | Phthalimide derivatives, their preparation and their use as agricultural fungicides | SANKYO COMPANY LIMITED (JP) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | GABRA1 3219/4885GABRB1 1999/4885CYP3A4 2610/4885 |
| US-12495715-B2 | Organic electroluminescent materials and devices | MCOLN2, MCOLN1, MCOLN3 | GABRA1 4229/4885GABRB1 3477/4885CYP3A4 1352/4885 |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | GABRA1 2431/4885GABRB1 1208/4885CYP3A4 2879/4885 |
| US-20020034764-A1 | DIARYLSULFONYLUREA BINDING PROTEINS | HSPBP1, IL1B, IL1RN | GABRA1 2343/4885GABRB1 1330/4885CYP3A4 3829/4885 |
| US-20260040813-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, MSRB3, GSR | GABRA1 1466/4885GABRB1 769/4885CYP3A4 1460/4885 |
| US-11981667-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | GABRA1 2480/4885GABRB1 1638/4885CYP3A4 266/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | GABRA1 2534/4885GABRB1 1507/4885CYP3A4 337/4885 |
| US-20240140973-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, LOXL1, OCIAD2 | GABRA1 2490/4885GABRB1 2656/4885CYP3A4 212/4885 |
| US-12012392-B2 | Sulfonamide carboxamide compounds | NLRP3, PYCARD, NOD1 | GABRA1 2660/4885GABRB1 2038/4885CYP3A4 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.